What question did this study set out to answer?

To compare the genomic features and clinical outcomes between paediatric and young adult patients and older adults with myeloproliferative neoplasms.

January 16, 2023British Journal of HaematologyOpen Access

Characterization of myeloproliferative neoplasms in the paediatric and young adult population

View Full Paper

Ask AI

Bookmark

Authors

ZHZoey I. HarrisMayo Clinic Hospital HKHannah KaizerJohns Hopkins University AWAria WeiThe University of Texas Southwestern Medical Center

Discussion

Member takes

Implication

Cohort study uncovers distinct genomic profiles and superior survival in young patients with myeloproliferative neoplasms, indicating distinct disease biology and management needs.

Key Points

To compare the genomic features and clinical outcomes between paediatric and young adult patients and older adults with myeloproliferative neoplasms.
Comparative cohort analysis of 630 patients with myeloproliferative neoplasms, stratified into paediatric and young adults (PAYA, <40 years, n=171) and older adults (OA, ≥40 years, n=459).
Evaluated clinical presentation, somatic mutations (JAK2, CALR, triple-negative), germline alterations, thrombotic complications, disease transformation, and survival.
PAYA patients more frequently presented with essential thrombocytosis (67% vs 39%; p < 0.001) and developed venous thrombosis (19.8% vs 10.7%; p = 0.002) compared to OA patients.
OA patients exhibited higher rates of JAK2 somatic mutations (80.4% vs 64.3%; p < 0.001), while PAYA patients had more CALR mutations (20.5% vs 10.5%; p = 0.001) and triple-negative disease (8.8% vs 3.7%; p = 0.01).
PAYA patients demonstrated superior survival (median not reached vs 13 years) and lower rates of disease transformation (19.3% vs 37.9%) relative to OA patients.

Cite This Study

Harris et al. (2023) studied this question.

synapsesocial.com/papers/6a10f86563b25c787d9fcf3e https://doi.org/10.1111/bjh.18650

View Full Paper

Ask AI

Bookmark

Implication

Cohort study uncovers distinct genomic profiles and superior survival in young patients with myeloproliferative neoplasms, indicating distinct disease biology and management needs.

Characterization of myeloproliferative neoplasms in the paediatric and young adult population

Discussion

Member takes

Implication

Key Points

Cite This Study

Characterization of myeloproliferative neoplasms in the paediatric and young adult population

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider